Evidence mapPaperPMID 41809460Full record

ReviewWorld journal of gastroenterology2026

Mechanisms and therapeutic potential of traditional Chinese medicine for inflammatory bowel disease.

Si-Hui Zeng, Xiao-Yan Jiang, De-Rong Lin, Wei-Jian Zhang, Yu-Qi Wu, Lin Xu, Shao-Ju Guo

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. International journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Si-Hui ZengDepartment of Spleen and Stomach Diseases, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, Guangdong Province, China.
Xiao-Yan JiangDepartment of Spleen and Stomach Diseases, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, Guangdong Province, China.
De-Rong LinDepartment of Acupuncture and Rehabilitation, Dongguan Hospital of Guangzhou University of Chinese Medicine, Dongguan 523000, Guangdong Province, China.
Wei-Jian ZhangDepartment of Spleen and Stomach Diseases, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, Guangdong Province, China.
Yu-Qi WuDepartment of Spleen and Stomach Diseases, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, Guangdong Province, China.
Lin XuDepartment of Spleen and Stomach Diseases, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, Guangdong Province, China.
Shao-Ju GuoDepartment of Spleen and Stomach Diseases, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518000, Guangdong Province, China. gsjgsjgsj2024@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of the intestine with a rising global incidence that significantly impairs patients' quality of life. Although modern medical therapies can provide short-term symptom relief, they are often limited by dependence on medication and considerable adverse effects. Traditional Chinese medicine (TCM) has demonstrated longstanding clinical efficacy and preclinical advantages in IBD management, yet systematic summaries and in-depth mechanistic insights remain insufficient. This minireview explores recent advances in the mechanistic research of TCM for IBD to inform alternative therapeutic strategies. A systematic literature search was conducted using databases including PubMed, Science Citation Index Expanded, and China National Knowledge Infrastructure to synthesize current evidence, focusing on literature published between 2023 and 2025. Findings reveal that TCM exerts therapeutic effects through holistic, multicomponent, multi-target, and multi-pathway regulation. Key mechanisms involve modulation of inflammatory signaling pathways, immune homeostasis, gut microbiota composition, intestinal barrier integrity, autophagy, metabolic functions, gene expression, and synergistic multi-target therapy. Despite existing research limitations, the evolution from empirical herbal use toward modern scientific understanding promises to accelerate the modernization and global integration of TCM. This minireview provides foundational insights for future research and clinical practice, with the potential to benefit IBD patients worldwide.

Indexed as

Drugs, Chinese HerbalInflammatory Bowel DiseasesMedicine, Chinese TraditionalAnimalsAutophagyGastrointestinal MicrobiomeHumansIntestinal Barrier FunctionIntestinal MucosaQuality of LifeSignal TransductionTreatment OutcomeDrugs, Chinese HerbalGut microbiotaImmune regulationInflammatory bowel diseaseInflammatory signalling pathwaysIntestinal barrier functionMechanismMulti-target therapyTraditional Chinese medicine

Identifiers

PMID41809460
PMCPMC12968607

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.